Sort
10,766 grants matching “checkpoint inhibitor”
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$373,547David E Fisher · Massachusetts General Hospital · R01 · FY2021 · CA
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$373,547David E Fisher · Massachusetts General Hospital · R01 · FY2020 · CA
Defining the determinants of response and resistance to therapy for Richter's Syndrome
$373,544Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2021 · CA
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$373,461Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2021 · AG
Melanoma-associated retinopathy: detection and mechanisms
$373,450Catherine W Morgans · Oregon Health & Science University · R01 · FY2021 · EY
Melanoma-associated retinopathy: detection and mechanisms
$373,450Catherine W Morgans · Oregon Health & Science University · R01 · FY2022 · EY
Control of Cell Fate and Proliferation in the Developing Eye
$373,447Utpal Banerjee · University Of California Los Angeles · R01 · FY2010 · EY
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
$373,258Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2021 · NS
Antitumor-Antibiotics from Marine Microorganisms
$373,010William Fenical · University Of California, San Diego · R37 · FY2012 · CA
Antitumor-Antibiotics from Marine Microorganisms
$373,010William Fenical · University Of California, San Diego · R37 · FY2011 · CA
Core B: Animal Model and Immunotyping Core
$372,966Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · P01 · FY2024 · CA
In Vivo Model of Epstein-Barr Virus Latency
$372,677Richard M Longnecker · Northwestern University At Chicago · R01 · FY2016 · CA
In Vivo Model of Epstein-Barr Virus Latency
$372,677Richard M Longnecker · Northwestern University At Chicago · R01 · FY2014 · CA
In Vivo Model of Epstein-Barr Virus Latency
$372,677Richard M Longnecker · Northwestern University At Chicago · R01 · FY2017 · CA
In Vivo Model of Epstein-Barr Virus Latency
$372,677Richard M Longnecker · Northwestern University At Chicago · R01 · FY2015 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$372,669Ann Richmond · Vanderbilt University · R01 · FY2022 · CA
p38 MAP kinase in early thymocyte development
$372,488Mercedes R. Rincon · University Of Vermont & St Agric College · R01 · FY2010 · AI
Combining senescence-inducing and senolytic agents to improve melanoma therapy
$372,444Anna E Vilgelm · Vanderbilt University · R37 · FY2019 · CA
CDC25 PHOSPHATASES IN CELL CYCLE CONTROL AND CANCER
$372,438Helen M Piwnica-Worms · Washington University · R01 · FY2011 · GM
Developmental Therapeutics
$372,411Dean G Tang · Roswell Park Cancer Institute Corp · P30 · FY2025 · CA
Reprogramming the Tumor Microenvironment in Pancreas Cancer to Enhance Immunotherapy
$372,237Nipun B. Merchant · University Of Miami School Of Medicine · R01 · FY2019 · CA